L Elit1, E B Kennedy2, A Fyles3, U Metser3. 1. Juravinski Cancer Centre, Hamilton, ON; 2. Program in Evidence-Based Care, Cancer Care Ontario and McMaster University, Hamilton, ON; 3. University Health Network, Toronto, ON.
Abstract
BACKGROUND: In 2009, the Program in Evidence-based Care (pebc) of Cancer Care Ontario published a guideline on the follow-up of cervical cancer. In 2014, the pebc undertook an update of the systematic review and clinical practice guideline for women in this target population. METHODS: The literature from 2007 to August 2014 was searched using medline and embase [extended to 2000 for studies of human papillomavirus (hpv) dna testing]. Outcomes of interest were measures of survival, diagnostic accuracy, and quality of life. A working group evaluated the need for changes to the earlier guidelines and incorporated comments and feedback from internal and external reviewers. RESULTS: One systematic review and six individual studies were included. The working group concluded that the new evidence did not warrant changes to the 2009 recommendations, although hpv dna testing was added as a potentially more sensitive method of detecting recurrence in patients treated with radiotherapy. Comments from internal and external reviewers were incorporated. RECOMMENDATIONS SUMMARY: Follow-up care after primary treatment should be conducted and coordinated by a physician experienced in the surveillance of cancer patients. A reasonable follow-up strategy involves visits every 3-4 months within the first 2 years, and every 6-12 months during years 3-5. Visits should include a patient history and complete physical examination, with elicitation of relevant symptoms. Vaginal vault cytology examination should not be performed more frequently than annually. Combined positron-emission tomography and computed tomography, other imaging, and biomarker evaluation are not advocated; hpv dna testing could be useful as a method of detection of recurrence after radiotherapy. General recommendations for follow-up after 5 years are also provided.
BACKGROUND: In 2009, the Program in Evidence-based Care (pebc) of Cancer Care Ontario published a guideline on the follow-up of cervical cancer. In 2014, the pebc undertook an update of the systematic review and clinical practice guideline for women in this target population. METHODS: The literature from 2007 to August 2014 was searched using medline and embase [extended to 2000 for studies of human papillomavirus (hpv) dna testing]. Outcomes of interest were measures of survival, diagnostic accuracy, and quality of life. A working group evaluated the need for changes to the earlier guidelines and incorporated comments and feedback from internal and external reviewers. RESULTS: One systematic review and six individual studies were included. The working group concluded that the new evidence did not warrant changes to the 2009 recommendations, although hpv dna testing was added as a potentially more sensitive method of detecting recurrence in patients treated with radiotherapy. Comments from internal and external reviewers were incorporated. RECOMMENDATIONS SUMMARY: Follow-up care after primary treatment should be conducted and coordinated by a physician experienced in the surveillance of cancerpatients. A reasonable follow-up strategy involves visits every 3-4 months within the first 2 years, and every 6-12 months during years 3-5. Visits should include a patient history and complete physical examination, with elicitation of relevant symptoms. Vaginal vault cytology examination should not be performed more frequently than annually. Combined positron-emission tomography and computed tomography, other imaging, and biomarker evaluation are not advocated; hpv dna testing could be useful as a method of detection of recurrence after radiotherapy. General recommendations for follow-up after 5 years are also provided.
Entities:
Keywords:
Cervical cancer; clinical practice guidelines; follow-up; surveillance; systematic reviews
Authors: Laurie Elit; Anthony W Fyles; Michaela C Devries; Thomas K Oliver; Michael Fung-Kee-Fung Journal: Gynecol Oncol Date: 2009-06-26 Impact factor: 5.482
Authors: R K Singh; S Maulik; S Mitra; R K Mondal; P S Basu; S Roychowdhury; C K Panda Journal: Int J Gynecol Cancer Date: 2006 May-Jun Impact factor: 3.437
Authors: B J Rimel; Aaron Ferda; Jamie Erwin; Summer B Dewdney; Leigh Seamon; Feng Gao; Christopher DeSimone; Kristen K Cotney; Warner Huh; L Stewart Massad Journal: Obstet Gynecol Date: 2011-09 Impact factor: 7.661
Authors: G P Browman; M N Levine; E A Mohide; R S Hayward; K I Pritchard; A Gafni; A Laupacis Journal: J Clin Oncol Date: 1995-02 Impact factor: 44.544
Authors: Rebecca A Brooks; Janet S Rader; Farrokh Dehdashti; David G Mutch; Matthew A Powell; Premal H Thaker; Barry A Siegel; Perry W Grigsby Journal: Gynecol Oncol Date: 2008-10-16 Impact factor: 5.482
Authors: C Meads; P Auguste; C Davenport; S Małysiak; S Sundar; M Kowalska; A Zapalska; P Guest; S Thangaratinam; P Martin-Hirsch; E Borowiack; P Barton; T Roberts; K Khan Journal: Health Technol Assess Date: 2013-03 Impact factor: 4.014
Authors: Beverley J Shea; Jeremy M Grimshaw; George A Wells; Maarten Boers; Neil Andersson; Candyce Hamel; Ashley C Porter; Peter Tugwell; David Moher; Lex M Bouter Journal: BMC Med Res Methodol Date: 2007-02-15 Impact factor: 4.615
Authors: A de Juan; A Redondo; M J Rubio; Y García; J Cueva; L Gaba; A Yubero; J Alarcón; C Maximiano; A Oaknin Journal: Clin Transl Oncol Date: 2020-01-24 Impact factor: 3.405
Authors: David Cibula; Lukáš Dostálek; Jiri Jarkovsky; Constantijne H Mom; Aldo Lopez; Henrik Falconer; Giovanni Scambia; Ali Ayhan; Sarah H Kim; David Isla Ortiz; Jaroslav Klat; Andreas Obermair; Giampaolo Di Martino; Rene Pareja; Ranjit Manchanda; Jan Kosťun; Ricardo Dos Reis; Mehmet Mutlu Meydanli; Diego Odetto; Rene Laky; Ignacio Zapardiel; Vit Weinberger; Klára Benešová; Martina Borčinová; Fernando Cardenas; Emelie Wallin; Luigi Pedone Anchora; Huseyin Akilli; Nadeem R Abu-Rustum; Salim Abraham Barquet-Muñoz; Veronika Javůrková; Daniela Fischerová; Luc R C W van Lonkhuijzen Journal: Gynecol Oncol Date: 2021-12-23 Impact factor: 5.304
Authors: Linus T Chuang; Sarah Temin; Rolando Camacho; Alfonso Dueñas-Gonzalez; Sarah Feldman; Murat Gultekin; Vandana Gupta; Susan Horton; Graciela Jacob; Elizabeth A Kidd; Kennedy Lishimpi; Carolyn Nakisige; Joo-Hyun Nam; Hextan Yuen Sheung Ngan; William Small; Gillian Thomas; Jonathan S Berek Journal: J Glob Oncol Date: 2016-05-25
Authors: Maarten G Thomeer; Vincent Vandecaveye; Loes Braun; Frenchey Mayer; Martine Franckena-Schouten; Peter de Boer; Jaap Stoker; Erik Van Limbergen; Marrije Buist; Ignace Vergote; Myriam Hunink; Helena van Doorn Journal: Eur Radiol Date: 2018-06-25 Impact factor: 5.315